INTRODUCTION
Psoriasis is a highly morbid inflammatory disease of variable duration, extent and severity that involves skin and/or joints and which may affect patients' quality of life [1] .
Biological drugs such as etanercept and adalimumab have considerably changed the therapeutic approach to this disease and enabled clinical control of a high proportion of patients [2, 3] . However, the substantial economic impact of these therapies on the national health system budget is a potential hindrance to their widespread use. The few costeffectiveness studies of biological therapies for psoriasis conducted to date have relied largely on clinical trials and have led to similar safety and efficiency results. Most of these studies involved incremental cost-effectiveness analyses of efficacy data obtained from clinical trials and adapted these to the social and economic peculiarities of the national health systems in the USA, Spain, Great Britain, Italy, Switzerland or Sweden, for example [4] [5] [6] [7] [8] [9] [10] . Thus, decision tree or hidden Markov models and Monte Carlo simulations were used to assess the cost-effectiveness of drugs such as infliximab [4] [5] [6] [7] [8] 10] , etanercept [4] [5] [6] [7] [8] [9] [10] , adalimumab [4] [5] [6] [7] [8] [9] [10] , efalizumab [4, 6, 7] , alefacept [8] and ustekinumab [7] . These studies measured effectiveness as the proportion of patients achieving a reduction of at least 75% with respect to the baseline value for the Psoriasis Area Severity Index (PASI 75) after 12 weeks [4] [5] [6] [7] [8] 10] , and additionally, after 24 or 48 weeks in some studies [6, 9] with a few studies also linking the results to quality of life [5, 9, 10] . However, all the studies that assessed the sensitivity of their incremental costeffectiveness estimates revealed an overlap between the studied drugs [4] [5] [6] [7] 11] . This is interesting as it reveals that effectiveness predictions from simulated data lead to similar results for different biological agents.
However, when trying to extrapolate such results into clinical practice, several factors need to be taken into consideration. For instance, clinical trials do not compare therapeutic choices, but rather individual drugs against a placebo. Also, most clinical trials comprise too short time periods to be representative of a disease, such as psoriasis, which has a chronic course that requires long-term treatment and where events occur that are usually not considered in these studies (e.g. suspension of the treatment after a period of sustained efficacy, dose elevations in response to recurrence, or withdrawal due to a lack or loss of efficacy or an adverse reaction). Moreover, the drugs used in clinical trials are administered in strict accordance with the recommendations in their technical sheets, but in clinical practice, there is evidence that physicians tend to manage patients using non-standard dosing patterns, intermediate doses, varying treatment interruption periods and increasing doses based on their own clinical judgement to achieve the therapeutic goal [12] . Based on this, we considered that observational studies providing a more accurate view of the use of biological drugs in clinical practice were required to test the hypothesis that etanercept and adalimumab exhibited no statistically significant differences in long-term costeffectiveness for the treatment of moderate-tosevere psoriasis in patients naïve to biological treatments [13] . This led us to assess the incremental cost-effectiveness of these drugs as first-choice biological treatments for moderate-to-severe plaque-type psoriasis using clinical practice data recorded at a reference hospital. and the urban bus fare when the transfer took place in the city, and the average cost of a 1-km ride in a medium-range car when the patient came from a different location [17] [18] [19] .
MATERIALS AND METHODS

Population and Design
Design
The time spent undergoing supplementary tests was not considered since many were performed at health centres near the patients'
homes. Also not considered were the time and costs associated with the administration of the drugs, since these were assumed to be essentially identical for both etanercept and adalimumab.
Effectiveness
Treatment effectiveness was measured as PASI 75, the main parameter of choice for assessing 
Costs
Cost analyses included direct costs (drug, healthcare resources, transportation) and indirect costs (productivity losses). Total associated costs were calculated by multiplying resource use by the corresponding unit cost. All costs are shown in euros (€) and updated to July 2012.
Economic Evaluation Method
The time frame of the analysis was 1 year. The study was conducted from a Spanish social perspective, which was judged to be the most complete format, as it considered both direct and indirect costs and included a social impact.
In this respect, the study departed from the usual, funder's approach.
Regimes and Monitoring
Incremental cost-effectiveness during the first 52 weeks of treatment was examined. Etanercept for adult treatment is available in subcutaneously administered 25 and 50 mg doses. The recommended dose is usually 25 mg twice a week or 50 mg once a week or, optionally, 50 mg twice a week [20] . The recommended dose for adalimumab is 40 mg administered subcutaneously every second week, starting 1 week after the initial dose [21] . The dose, dosing interval and duration of the treatment regimen for each drug until its indefinite suspension were recorded. Costs associated with adverse reactions were excluded.
Statistical Analysis
The statistical methods used to describe centrality and dispersion of the data were the relative frequency (absolute frequency), followed by the minimum and maximum value for categorical variables and the arithmetic mean ± standard deviation for quantitative variables. Statistically significant differences between the two treatments were established with the Chi-squared test for categorical variables and the Kruskall-Wallis test for quantitative variables. All computations were performed using different packages of the 'R' statistical software system [22] .
RESULTS
Demographics and Patient Characteristics
We Table 1 . There were no statistically significant differences between the two drug groups in most of the parameters. The only differences observed were in the frequencies of allergic rhinitis and asthmatic bronchitis (both P\0.001, respectively). All other characteristics were similar in both treatment groups; therefore we deemed these differences to be irrelevant when interpreting the results. During the first year, there were 14 dropouts (3: lack of adherence; 7:
loss of efficacy; 4 adverse events). Only in four patients (3 in the etanercept group and 1 in the adalimumab group) was the drug withdrawn due to adverse reactions, but the adverse events were described accurately in the clinical history of only one of these cases. Table 2 shows that the costs of an internal medicine specialist outpatient and day hospital visits, simple X-rays and dermatology inpatient visits were lower for etanercept as compared to adalimumab (all P\0.05). Nevertheless, there were no significant differences in total healthcare resource costs between both treatment groups. When analysing work productivity losses (Table 3 ) and patients' transportation expenditure (Table 4) , a significant increase was found in the cost associated with visits to the internal medicine specialist in the group treated with adalimumab compared with etanercept (all P\0.05). However, these differences did not contribute to the total work productivity losses or patients' transportation costs, which resulted in no statistically different overall costs between both drugs. Table 5 shows the total cost of each treatment choice. There were no significant differences in total cost per patient with etanercept compared with adalimumab.
Cost-Effectiveness Analysis
The absence of statistically significant differences in effectiveness between the two treatments excluded a cost-effectiveness analysis, which was replaced with a cost minimization analysis. This included not only drug costs, but also direct costs derived from the use of resources, patients' transportation and indirect (work productivity loss) costs.
DISCUSSION
This study approached cost-effectiveness analysis from a novel, broad perspective, in social terms and based on observational data.
This strengthens the applicability of its results to similar populations, as it reduces uncertainty in the decision-making process in clinical practice when using estimates of pharmacoeconomic studies based on clinical trial data.
However, our approach is subject to several methodological limitations that warrant some comment. The single-centre, retrospective design used in this study may have detracted from the representative nature of the results owing to inaccuracies in the patients' clinical histories. This potential bias, which is inherent in most retrospective work, is a result of the lack of well-defined standards for recording visits and of variability in clinical practice-two distinct features of clinical trial designs. In any case, our results could be validated by a future standardized, multi-centre, prospective study.
One other potential shortcoming of our study was the exclusion of costs arising from the management of adverse reactions to etanercept and adalimumab. The exclusion of large number of patients in the adalimumab group had psoriatic arthritis in addition to plaque psoriasis; therefore, these patients were excluded to avoid biased estimation of the costs associated with the use of health-care resources.
Also, alternative biologicals currently in use to treat moderate-to-severe psoriasis in our hospital (e.g. infliximab and ustekinumab)
were excluded, since they are administered intravenously and only at the hospital-a marked difference from etanercept and adalimumab. In addition, these alternative biological agents are prescribed mostly for patients with arthritis and/or those selected for rescue with other biologicals. In addition, the use frequency of ustekinumab as a first-choice SD standard deviation;, n.a. not applicable, n.s. not significant * Kruskall-Wallis test for the quantitative variable 'mean cost per patient' comparing both drugs biological agent in our patient cohortprobably as a result of its more recent commercialization-was too low to enable its cost analysis during the first year of treatment.
In any case, we believe our analysis is representative of daily clinical practice since it compares two drugs, which jointly accounted for 70.4% of our hospital's expenditure on biologicals for the treatment of psoriasis during the studied period. Based on our results, there are no significant differences in efficiency or total cost per patient when etanercept is compared with adalimumab for moderate-to-severe psoriasis not associated with arthritis. Although the overall analysis showed no differences in direct and indirect costs between both drugs, in the specific subanalyses, an increase in direct and indirect costs associated with internal medicine outpatient and day hospital visits, and simple X-rays was found in the adalimumab group as compared to the etanercept group. As there were no differences in the baseline characteristics of patients in each treatment group, a possible explanation is that a selection bias could have been introduced by dermatologists in choosing adalimumab for individuals with non-specific rheumatic symptoms. These symptoms are likely to have motivated the patient to consult the internal medicine specialist. Nevertheless, we know of no data in the clinical history reviewed to support this hypothesis.
In the virtual absence of similar studies, ours can be used as an additional source of information towards placing both etanercept and adalimumab as primary choices for the treatment of plaque-type psoriasis within the scope of the Spanish National Health System.
Some design-related factors can alter one's perception of the usefulness of previous studies on this topic. Unlike previous studies, ours provides an approach to a difficult problem that is akin to clinical practice based on real-life There are also some limitations to comparing our results with those of others based on clinical practice owing to differences in study design, variables and objectives. Fonia et al. analysed drug and health-care resource-related costs in a historical cohort of patients with psoriasis seen at a third-level hospital in Great Britain [24] and found the expected increase in costs derived from the introduction of biological agents to be accompanied by a decrease in use of hospital resources by the patients. However, these authors failed to examine costs in terms of the particular drug, which precludes comparison with our results. Subject to similar constraints is the study by Wu et al. [25] , who used a USAbased health database to compare the costs of 
CONCLUSION
In summary, our data suggest that etanercept is as cost-effective as adalimumab during the first year of treatment in patients with moderate-tosevere psoriasis not associated with arthritis.
